Evidence map›Paper›PMID 40636141›Full record

ReviewiLIVER2022

Liver transplantation for malignant liver tumors.

Richard X Sousa Da Silva, Beat Muellhaupt, Philipp Dutkowski, Pierre-Alain Clavien

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in iLIVER, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Richard X Sousa Da SilvaDepartment of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) and Transplant Center, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.
Beat MuellhauptDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.
Philipp DutkowskiDepartment of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) and Transplant Center, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.
Pierre-Alain ClavienDepartment of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) and Transplant Center, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver transplantation is a highly effective treatment not only for acute or chronic liver failure but also for primary liver cancer such as hepatocellular carcinoma, perihilar cholangiocarcinoma, intrahepatic cholangiocarcinoma, and metastatic tumors such as from neuroendocrine or colorectal liver metastases. The success strongly relies on strict adherence to stringent selection criteria, which lead to excellent outcomes, while previously regarded as contraindication for liver transplantation. These impressive results are, however, mostly achieved with a combination of pretreatment strategies and convincing control of the tumor growth prior to transplantation, as well as minimizing long-term immunosuppression. With this emergence of oncologic liver transplantation, we expect an increasing need of grafts, and therefore included in this report strategies to improve the number of available grafts by maximizing liver utilization rates. Modern machine liver perfusion approaches may play in this respect an important role.

Indexed as

Liver transplantationMachine perfusionMalignant tumorSelection criteriaTumor recurrence

Identifiers

PMID40636141
PMCPMC12212609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.